Physician profile
Christopher E Gee
NPI 1245398734
$20,834.16
in general payments reported to CMS, 2019-2025
55 companies · $3,358 in 2025
The $3,358 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $1,778 · 2021: $4,798 · 2022: $2,333 · 2023: $3,504 · 2024: $3,855 · 2025: $3,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,536.03 |
| Education | $180.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,593.64 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,694.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $1,536.86 | 2021 | |
| Glaxosmithkline, LLC. | $1,497.09 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $1,353.45 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,216.72 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Amgen INC. | $1,091.87 | 2021-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $925.67 | 2019-2025 | Veozah, Izervay, Myrbetriq |
| Lilly USA, LLC | $891.54 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $793.45 | 2019-2025 | Verquvo, Gardasil 9, Belsomra |
| Pfizer INC. | $732.10 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $556.27 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $543.64 | 2022-2025 | Quviviq, Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $543.47 | 2022-2025 | |
| Eisai INC. | $407.92 | 2020-2025 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.